Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

Ixekizumab helps improve life quality, physical ability, and work performance in patients with psoriatic arthritis who haven't used biologic drugs before.

This review discusses the challenges in diagnosing and managing asthma in older adults and reports no new results; the authors emphasize the importance of addressing comorbidities and potential medication adverse events.

This review discusses the approval of deuruxolitinib, an oral JAK inhibitor, by the FDA in July 2024 for treating severe alopecia areata in adults, highlighting its role as the third approved oral treatment option alongside baricitinib and ritlecitinib.

This case report details a young female patient's experience of transient hair loss after starting omalizumab (anti-IgE) for chronic urticaria, noting that she continued the treatment for 10 months with positive outcomes despite this side effect.

This study observed that oclacitinib, combined with oral glucocorticoids, achieved rapid and lasting clinical remission in four dogs with refractory juvenile-onset ischaemic dermatopathy, suggesting oclacitinib's potential as a useful immunosuppressive treatment in such cases.

This CADTH recommendation advises that Olumiant should be publicly reimbursed for treating severe alopecia areata in adults, provided conditions such as a 50% scalp hair loss and specific prescribing criteria are met.

In this case study, treatment with the selective JAK1 inhibitor upadacitinib significantly improved symptoms in a patient with refractory alopecia areata, vitiligo, ankylosing spondylitis, and allergic asthma-nasal syndrome, though a transient liver function abnormality was noted.

In this case report, a 7-year-old girl with severe alopecia areata and high baseline IgE levels achieved complete hair regrowth after 48 weeks of dupilumab therapy, with observed decreases in IgE levels and no significant adverse effects beyond a mild initial allergic reaction.

This review discusses the controversial non-inflammatory alopecia known as alopecia X, highlighting its unknown etiology and the variable effectiveness of various proposed treatments, but reports no new results.

This review examines existing research and clinical trials on the use of dupilumab for various skin, respiratory, and gastrointestinal disorders, but it reports no new clinical findings.

In a proof-of-concept study at Xiangya Hospital, the researchers observed that combining tofacitinib with low-dose interleukin-2 helped maintain remission in refractory alopecia areata patients, with three out of four maintaining complete remission for 11–20 months post-treatment and no adverse events reported.

This study demonstrated that a new topical treatment using ketotifen-loaded microneedles, designed for prolonged release, significantly reduced inflammatory markers in an animal model of allergic conjunctivitis, suggesting enhanced therapeutic delivery and sustained ocular benefits.

The trial helped find the best dose of deuruxolitinib for treating alopecia areata.

This study explored the experiences of systemic lupus erythematosus patients receiving Anifrolumab, revealing improvements in self-reported symptoms and daily life impacts alongside decreased disease activity and lowered corticosteroid use.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

Actemra is approved for a specific artery condition, HIV treatment adherence has improved, women may pay more for a hair loss product, and incorrect dosing of blood thinners can be risky.

This study found that both oral afoxolaner (NexGard®) and topical Frontline Combo® achieved 100% efficacy in eradicating Heterodoxus spiniger infestations within 30 days in dogs, with significant reductions in associated symptoms like hair loss and pruritus.

This study found that activating liver X receptors with an agonist reduced skin fibrosis in experimental models, particularly in inflammation-driven conditions, by inhibiting macrophage infiltration and interleukin-6 release.

Deuruxolitinib is generally safe for treating alopecia areata.

This study found that among anti-TNF-α agents, certolizumab is the least likely to cause paradoxical reactions such as psoriatic alopecia and appears to be an effective and safe option for managing psoriasis and PsA while minimizing these risks.

In this study, JAK inhibitors like baricitinib and ruxolitinib were found to be more effective and caused fewer discontinuations due to adverse events in adults with alopecia areata compared to therapies like dupilumab and apremilast, highlighting the need for more high-quality comparative trials.

Deuruxolitinib effectively promotes hair regrowth in alopecia areata.

This study found that in mouse models, the novel NF-κB inhibitor DHMEQ improved symptoms of atopic dermatitis as effectively as tacrolimus or betamethasone.

Apremilast may help treat hair loss in alopecia areata.

This study aimed to evaluate the outcomes of switching between two JAK inhibitors, tofacitinib and baricitinib, in treating alopecia areata, due to the lack of data on their comparative efficacy.

This study reports a case where subcutaneous aeroallergen immunotherapy led to hair regrowth in a child with seasonal alopecia areata linked to rhinitis and allergen sensitivity, maintaining results over four years with some residual symptoms.